Atlas FDA

NOVOCURE LTD'S NOVOTTF-100A TREATMENT KIT

FDA premarket approval P100034 · decided 2011-04-08

Approval details

PMA number
P100034
Trade name
NOVOCURE LTD'S NOVOTTF-100A TREATMENT KIT
Generic name
Stimulator, low electric field, tumor treatment
Applicant
Novocure, GmbH
Date received
2010-08-16
Decision date
2011-04-08
Days to decision
235 days
Decision code
APPR
Product code
NZK
Advisory committee
Neurology
Expedited review
Yes
Location
Baar
Statement
APPROVAL FOR THE NOVOTTF-100A SYSTEM. THE DEVICE IS INDICATED FOR TREATMENT OF ADULT PATIENTS (22 YEARS OF AGE OR OLDER) WITH HISTOLOGICALLY- CONFIRMED GLIOBLASTOMA MULTIFORME, FOLLOWING HISTOLOGICALLY- OR RADIOLOGICALLY- CONFIRMED RECURRENCE IN THE SUPRATENTORIAL REGION OF THE BRAIN AFTER RECEIVING CHEMOTHERAPY. THE DEVICE IS INTENDED TO BE USED AS A MONOTHERAPY, AND IS INTENDED AS AN ALTERNATIVE TO STANDARD MEDICAL THERAPY FOR GBM AFTER SURGICAL AND RADIATION OPTIONS HAVE BEEN EXHAUSTED.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.